scPharmaceuticals (SCPH) Revenue & Revenue Breakdown
scPharmaceuticals Revenue Highlights
Latest Revenue (Y)
$13.59M
Latest Revenue (Q)
$6.10M
scPharmaceuticals Revenue by Period
scPharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $13.59M | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | - |
scPharmaceuticals generated $13.59M in revenue during NA 2023, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
scPharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $6.10M | 0.10% |
| 2023-12-31 | $6.10M | 60.59% |
| 2023-09-30 | $3.80M | 131.75% |
| 2023-06-30 | $1.64M | -20.60% |
| 2023-03-31 | $2.06M | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | - |
scPharmaceuticals generated $6.10M in revenue during Q1 2024, up 0.10% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
scPharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| MCRB | Seres Therapeutics | $126.33M | - |
| SCPH | scPharmaceuticals | $13.59M | $6.10M |
| CNTA | Centessa Pharmaceuticals | $6.88M | - |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| IOVA | Iovance Biotherapeutics | $1.19M | $31.11M |
| MIST | Milestone Pharmaceuticals | $1.00M | - |
| LIFE | aTyr Pharma | $353.00K | $235.00K |
| SCPS | Scopus BioPharma | - | - |
| DMAC | DiaMedica Therapeutics | - | - |
| MNPR | Monopar Therapeutics | - | - |
| ONCY | Oncolytics Biotech | - | - |
| KTTA | Pasithea Therapeutics | - | - |
SCPH Revenue FAQ
What is scPharmaceuticals’s yearly revenue?
scPharmaceuticals's yearly revenue for 2023 was $13.59M, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. SCPH's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is scPharmaceuticals’s quarterly revenue?
scPharmaceuticals's quarterly revenue for Q1 2024 was $6.1M, a 0.10% increase from the previous quarter (Q4 2023), and a 195.78% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $6.1M, a 60.59% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022). SCPH's quarterly revenue for Q3 2023 was $3.8M, a 131.75% increase from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022).
What is scPharmaceuticals’s revenue growth rate?
scPharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.